Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome

Matzen, Sara Maj Hyldig; Raaschou‐Jensen, Klas; Kallenbach, Klaus

doi:10.1002/hsr2.90

Cited by 6 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MFC will complement the primary morphological evaluation, especially in borderline cases where immunophenotypic aberrations can support or exclude MDS diagnosis (as illustrated in a diagnostic algorithm presented in Figure 1 in . The previous iMDSflow recommendation that the four-parameter Ogata score (Ogata et al, 2009) may be used for a preliminary assessment of MFC dysplasia has been confirmed by several publications (Bardet et al, 2015;Dhingra et al, 2020;Grille Montauban et al, 2019;Kárai et al, 2017;Mannelli et al, 2019;Matzen et al, 2018;Muyldermans et al, 2019;. This score is based on the frequency of myeloid CD34 + myeloid progenitors (MP) (>2%), the fraction of B-cell precursors within CD34 + cells (<5%), abnormal CD45 expression on CD34 + blasts, and low granulocyte scatter (granulocyte/lymphocyte SSC ratio ≤6).…”

Section: Minimal Requirements To Assess Dysplasia By Mfcmentioning

confidence: 97%

“…In the first publication, the frequency of B‐cell precursors was evaluated using gating based on forward vs. side scatter properties (Ogata et al, 2009 ). However, most laboratories nowadays include CD19 to increase precision (Guo et al, 2020 ; Matzen et al, 2018 ; Rajab & Porwit, 2015 ). The four parameters carry different weights in the evaluation of dysplasia.…”

Section: Minimal Requirements To Assess Dysplasia By Mfcmentioning

confidence: 99%

See 1 more Smart Citation

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Porwit

Béné

Duetz

et al. 2022

Cytometry Part B Clinical

View full text Add to dashboard Cite

Multiparameter flow cytometry (MFC) is one of the essential ancillary methods in bone marrow (BM) investigation of patients with cytopenia and suspected myelodysplastic syndrome (MDS). MFC can also be applied in the follow-up of MDS patients undergoing treatment. This document summarizes recommendations from the International/European Leukemia Net Working Group for Flow Cytometry in Myelodysplastic Syndromes (ELN iMDS Flow) on the analytical issues in MFC for the diagnostic work-up of MDS. Recommendations for the analysis of several BM cell subsets such as myeloid precursors, maturing granulocytic and monocytic components and erythropoiesis are given. A core set of 17 markers identified as independently related to a cytomorphologic diagnosis of myelodysplasia is suggested as mandatory for MFC evaluation of BM in a patient with cytopenia. A myeloid precursor cell (CD34 + CD19 À ) count >3% should be considered immunophenotypically indicative of myelodysplasia. However, MFC results should always be evaluated as part of an integrated hematopathology work-up. Looking forward, several machinelearning-based analytical tools of interest should be applied in parallel to

show abstract

Section: Minimal Requirements To Assess Dysplasia By Mfcmentioning

confidence: 97%

Section: Minimal Requirements To Assess Dysplasia By Mfcmentioning

confidence: 99%

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Porwit

Béné

Duetz

et al. 2022

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…FACS Lysing Solution and a stain-lyse-wash protocol, which we used, significantly reduce the light scatter CV for the different leukocyte populations compared to ammonium chloride [ 31 ], and may therefore influence the granulocyte/lymphocyte SSC ratio. However, this staining procedure did not decrease the sensitivity of the Ogata score in our cohort, and Matzen et al also used FACS Lysing solution with high specificity in their MDS analysis [ 32 ], so the FACS Lysing solution is unlikely to have a significant effect on the SSC ratio. The specificity of the “3 aberrations in two cell compartments method” was found to be higher (79%), although this figure is still far from 100%.…”

Section: Discussionmentioning

confidence: 74%

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

Plander,

Kányási,

Szendrei

et al. 2024

Pathol. Oncol. Res.

View full text Add to dashboard Cite

BackgroundMyelodysplastic neoplasms (MDS) are characterized by cytopenia, morphologic dysplasia, and genetic abnormalities. Multiparameter flow cytometry (FCM) is recommended in the diagnostic work-up of suspected MDS, but alone is not sufficient to establish the diagnosis. Our aim was to investigate the diagnostic power of FCM in a heterogeneous population of patients with cytopenia, excluding cases with increased blast count.MethodsWe analyzed bone marrow samples from 179 patients with cytopenia (58 MDS, 121 non-MDS) using a standardized 8-color FCM method. We evaluated the sensitivity, specificity, and accuracy of several simple diagnostic approaches, including Ogata score, extended Ogata score, the WHO and ELN iMDSFlow recommended “3 aberrations in two cell compartments method,” and the combination of the Ogata score and “3 aberrations in two cell compartments method.” The patients were followed until the diagnosis was confirmed, with a median follow-up of 2 months (range 0.2–27).ResultsThe combination of Ogata score and “3 aberrations in two cell compartments method” achieved the highest diagnostic accuracy (78%) with sensitivity and specificity 61% and 86%, respectively. When using only the “3 aberrations in two cell compartments method,” the accuracy was 77% with a sensitivity of 72% and a specificity of 79%. The most frequently observed etiologies among the false positive cases were substrate deficiencies, inflammation/infection, or toxic effects. MDS can be excluded in all these cases after a thorough clinical evaluation and a relatively short follow-up.ConclusionFCM remains an important but supplementary part in an integrated diagnostic process of MDS with low blasts. The combination of the Ogata score and the “3 aberrations in two cell compartments method” slightly improves accuracy compared to the detection of “3 aberrations in two cell compartments method” alone.

show abstract

“…Therefore, many other study groups have achieved similar diagnostic values. 15,16 Since the time when the Ogata score was published, numerous related scales have been created for the diagnosis of MDS, many of which assume the assessment of similar parameters. Karai et al extended this scale to include erythrocyte maturation cell lines by adding CD71 and mast cell percentage, achieving higher sensitivity (84%) for low-grade MDS.…”

Section: Cytometric Scales In the Diagnosis Of Myelodysplastic Syndromesmentioning

confidence: 99%

The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience

et al. 2021

View full text Add to dashboard Cite

Introduction: This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS). Materials and methods: The study group consisted of patients who underwent diagnostic process in the years 2008-2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.Results: The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0-5) vs 0 (range 0-2); P < .0001]. Similarly, the median Ogata score was significantly higher in the MDS group [2 (range 0-4) vs 1 (range 0-3); P < .0001].Since the disturbances of the CD11b/HLA-DR and CD11b/CD13 on granulocytes were significantly more common in MDS patients, the Ogata score was extended by these abnormalities, what resulted in its higher diagnostic sensitivity (82%) while preserving high specificity (87%). The positive correlation was found between risk score determined by the Revised International Prognostic Scoring System and the number of the BM immunophenotypic abnormalities (P = .017). Conclusions: Our results indicate that the diagnostic usefulness of the Ogata score may be increased by including the abnormal expression of CD11b/HLA-DR and CD11b/CD13 on granulocytes. Moreover, our findings suggest the prognostic significance of the number of BM cytometric abnormalities in MDS. 2 of 12 | MAJCHEREK Et Al. How to cite this article: Majcherek M, Kiernicka-Parulska J, Mierzwa A, et al. The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single-centre real-life experience.

show abstract

Implementation of the Ogata flow cytometric scoring system in routine diagnostics of myelodysplastic syndrome

Cited by 6 publications

References 16 publications

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience

Contact Info

Product

Resources

About